Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 57.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,422 shares of the biopharmaceutical company’s stock after selling 3,265 shares during the period. Sterling Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $598,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Bank of Nova Scotia raised its stake in shares of Alnylam Pharmaceuticals by 0.6% during the first quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock valued at $2,580,000 after purchasing an additional 49 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in Alnylam Pharmaceuticals by 27.8% in the third quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 49 shares during the period. Prestige Wealth Management Group LLC lifted its holdings in Alnylam Pharmaceuticals by 30.6% in the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 53 shares during the period. Fortitude Family Office LLC grew its position in Alnylam Pharmaceuticals by 10.5% in the 3rd quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 55 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its position in Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 56 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. UBS Group initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 15th. They set a “buy” rating and a $354.00 target price on the stock. TD Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Stifel Nicolaus reduced their price objective on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $364.95.

Alnylam Pharmaceuticals Stock Up 2.5%

Shares of ALNY opened at $232.40 on Thursday. The company has a 50-day simple moving average of $239.15 and a 200-day simple moving average of $288.34. The firm has a market capitalization of $31.10 billion, a P/E ratio of 43.20 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $482.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same period last year, the business earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.